El remedy for psoriasis.Pharmaceutics 2013, 5 AcknowledgmentsWe acknowledge the monetary assistance of Stiefel and the EPRSC National Mass Spectrometry Service, University of Swansea, UK, for high resolution mass spectrometry. References 1. 2. 3. four. 5. 6. 7. Christophers, E. Psoriasis–Epidemiology and clinical spectrum. Clin. Exp. Dermatol. 2001, 26, 31420. Gordon, K.B.; Ruderman, E.M. The treatment of psoriasis and psoriatic arthritis: An interdisciplinary method. J. Am. Acad. Dermatol. 2006, 54, S86 91. R z, E.; Prens, E.P. Molecular pathophysiology of psoriasis and molecular targets of antipsoriatic therapy. Professional Rev. Mol. Med. 2009, 11, e38. Clark, A.R. Topical noncorticosteroid therapies for psoriasis. Curr. Probl. Dermatol. 2000, 12, 23032. Ryan, C.; Abramson, A.; Patel, M.; Menter, A. Existing investigational drugs in psoriasis. Expert Opin. Investig. Drugs 2012, 21, 47387. Gillard, S.E.; Finlay, A.Y. Present management of psoriasis inside the united kingdom: D3 Receptor Inhibitor Compound Patterns of prescribing and resource use in main care. Int. J. Clin. Pract. 2005, 59, 1260267. Lau, W.M.; White, A.W.; Gallagher, S.J.; Donaldson, M.; McNaughton, G.; Heard, C.M. Scope and limitations of the co-drug method to topical drug delivery. Curr. Pharm. Des. 2008, 14, 79402. M ler, K.; Leukel, P.; Mayer, K.K.; Wiegrebe, W. Modification of DNA bases by anthralin and connected compounds. Biochem. Pharmacol. 1995, 49, 1607613. McGill, A.; Frank, A.; Emmett, N.; Turnbull, D.M.; Birch-Machin, M.A.; Reynolds, N.J. The antipsoriatic drug anthralin accumulates in keratinocyte mitochondria, dissipates mitochondrial membrane prospective, and induces apoptosis by way of a pathway dependent on respiratory competent mitochondria. FASEB J. 2005, 19, 1012014. Peus, D.; Beyerle, A.; Vasa, M.; Pott, M.; Meves, A.; Pittelkow, M.R. Antipsoriatic drug anthralin induces egf receptor phosphorylation in keratinocytes: Requirement for H2O2 generation. Exp. Dermatol. 2004, 13, 785. Reichert, U.; Jacques, Y.; Grangeret, M.; Schmidt, R. Antirespiratory and antiproliferative activity of anthralin in cultured human keratinocytes. J. Invest. Dermatol. 1985, 84, 13034. Van Duuren, B.L.; Segal, A.; Tseng, S.S.; Rusch, G.M.; Loewengart, G.; Mate, U.; Roth, D.; Smith, A.; Melchionne, S.; Seidman, I. Structure and tumor-promoting activity of analogs of anthralin (1,8-dihydroxy-9-anthrone). J. Med. Chem. 1978, 21, 261. Mahrle, G. Dithranol. Clin. Dermatol. 1997, 15, 72337. M ler, K.; Breu, K.; Reindl, H. 10-Phenylbutyryl-substituted anthracenones as inhibitors of keratinocyte development and ltb4 biosynthesis. Eur. J. Med. Chem. 2001, 36, 17984. M ler, K.; Altmann, R.; Prinz, H. 10-Benzoyl-1,8-dihydroxy-9(10H)-anthracenones: Synthesis and biological properties. Eur. J. Med. Chem. 1998, 33, 20914.eight. 9.10.11. 12.13. 14. 15.Pharmaceutics 2013,16. Prinz, H.; Wiegrebe, W.; M ler, K. Syntheses of anthracenones. three. Revised preparative route to 10-benzoyl-1,8-dihydroxy-9(10H)-anthracenones. J. Org. Chem. 1996, 61, 2861864. 17. Lau, W.M.; White, A.W.; Heard, C.M. Topical delivery of a naproxen-dithranol co-drug: In vitro skin penetration, permeation, and staining. Pharm. Res. 2010, 27, 2734742. 18. Bos, J.D.; Meinardi, M. The 500 dalton rule for the skin penetration of chemical compounds and drugs. Exp. Dermatol. 2000, 9, 16569. 19. Lau, W.M.; Ng, K.W.; White, A.W.; Heard, C.M. Therapeutic and FP Antagonist web cytotoxic effects from the novel antipsoriasis codrug, naproxyl-dithranol, on hacat cells. Mol. Pharm. 2011, 8, 2398407. 20.